Durham, United Kingdom
Magnitude Biosciences Ltd, founded in 2018, is an innovative biotechnology startup headquartered in the United Kingdom. This company leverages its proprietary WormGazer® Technology to deliver non-invasive assays using C. elegans for industries like biotech, nutrition, and pharmaceuticals. The technology aims to de-risk clinical trials and cut costs significantly.
With a focus on prescreening compounds to limit mammalian experiments and finding effective concentration ranges, Magnitude Biosciences addresses pertinent challenges in drug discovery. The company has been successful in integrating C. elegans into drug pipelines and designing customized studies for aging research, validating its platform in collaboration with innovative biotech and pharma firms.
The latest funding milestone was a Seed Round investment completed on 14 November 2022. Despite no disclosed investors, this funding positions the company to further solidify its technological advancements and expand its reach across sectors.
